NASDAQ : DRUG
Bright Minds Biosciences Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 54.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 544.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year October - September; amounts in CAD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.18M | 2.53M | 1.45M | 2.20M | 2.55M | 2.31M |
| Research & Development | 32.74M | 11.08M | 1.18M | 5.00M | 12.18M | 6.31M |
| Operating Expenses | 39.18M | 13.61M | 2.63M | 7.20M | 14.73M | 8.62M |
| Operating Income | -39.18M | -13.61M | -2.63M | -7.20M | -14.73M | -8.62M |
| Interest Expense | -52.00K | -35.85K | ||||
| Interest & Investment Income | 6.83M | 1.52M | 30.13K | |||
| Currency Exchange Gain (Loss) | 8.24M | 188.77K | -9.31K | 14.19K | 12.15K | 154.10K |
| Other Non Operating Income (Expenses) | -348.47K | -287.65K | -197.19K | -186.65K | -243.08K | -181.74K |
| EBT Excluding Unusual Items | -24.51M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Asset Writedown | -2.00K | |||||
| Pretax Income | -24.51M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Net Income | -24.51M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Net Income to Common | -24.51M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Shares Outstanding (Basic) | 8.60M | 6.88M | 4.31M | 3.72M | 2.47M | 1.79M |
| Shares Outstanding (Diluted) | 8.60M | 6.88M | 4.31M | 3.72M | 2.47M | 1.79M |
| EPS (Basic) | -2.85 | -1.78 | -0.65 | -1.98 | -6.06 | -4.82 |
| EPS (Diluted) | -2.86 | -1.78 | -0.65 | -1.98 | -6.06 | -4.82 |
| EBIT | -39.18M | -13.61M | -2.63M | -7.20M | -14.73M | -8.62M |
Balance sheet
Fiscal year October - September; amounts in CAD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 307.83M | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Cash & Short-Term Investments | 307.83M | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Other Receivables | 1.10M | 413.07K | 50.22K | 36.98K | 155.78K | 110.15K |
| Receivables | 1.10M | 413.07K | 50.22K | 36.98K | 155.78K | 110.15K |
| Prepaid Expenses | 1.35M | 987.91K | 216.63K | 27.69K | 164.43K | 168.21K |
| Total Current Assets | 310.28M | 84.31M | 5.99M | 6.81M | 11.95M | 20.04M |
| Property, Plant & Equipment | 52.92K | 111.97K | 117.66K | 66.41K | 138.86K | |
| Other Intangible Assets | 2.00K | |||||
| Total Assets | 310.34M | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Accounts Payable | 2.36M | 1.71M | 407.55K | 182.31K | 1.25M | 596.57K |
| Accrued Expenses | 113.77K | 540.55K | 41.75K | 25.00K | 158.18K | 42.00K |
| Current Portion of Leases | 65.59K | 84.53K | 79.38K | 73.55K | 67.93K | |
| Total Current Liabilities | 2.54M | 2.34M | 528.68K | 280.86K | 1.47M | 638.57K |
| Long-Term Leases | 41.25K | 39.58K | 71.98K | |||
| Total Liabilities | 2.54M | 2.38M | 568.26K | 280.86K | 1.54M | 638.57K |
| Common Stock | 365.98M | 123.25M | 35.42M | 33.91M | 32.24M | 27.08M |
| Retained Earnings | -67.00M | -46.58M | -34.35M | -31.55M | -24.17M | -9.21M |
| Comprehensive Income & Other | 8.82M | 5.37M | 4.46M | 4.23M | 2.48M | 1.53M |
| Shareholders' Equity | 307.79M | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
| Total Liabilities & Equity | 310.34M | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Total Debt | 65.59K | 125.78K | 118.96K | 73.55K | 139.91K | |
| Net Cash (Debt) | 307.76M | 82.78M | 5.60M | 6.67M | 11.49M | 19.76M |
| Net Cash Per Share | 35.79 | 12.04 | 1.30 | 1.79 | 4.65 | 11.01 |
| Filing Date Shares Outstanding | 9.86M | 7.79M | 6.99M | 4.46M | 3.74M | 2.37M |
| Total Common Shares Outstanding | 9.86M | 7.64M | 4.52M | 3.77M | 3.52M | 2.37M |
| Working Capital | 307.74M | 81.97M | 5.46M | 6.53M | 10.48M | 19.40M |
| Book Value Per Share | 31.20 | 10.74 | 1.22 | 1.75 | 3.00 | 8.20 |
| Tangible Book Value | 307.79M | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
| Tangible Book Value Per Share | 31.20 | 10.74 | 1.22 | 1.75 | 3.00 | 8.20 |
Cash flow statement
Fiscal year October - September; amounts in CAD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -24.51M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Depreciation & Amortization | 76.06K | 76.87K | 73.36K | 72.45K | 6.04K | |
| Asset Writedown & Restructuring Costs | 2.00K | |||||
| Stock-Based Compensation | 5.11M | 3.18M | 839.77K | 1.15M | 902.31K | 880.62K |
| Other Operating Activities | -5.82M | -276.84K | -1.18K | 65.10K | -256.65K | 144.76K |
| Change in Accounts Payable | 1.95M | 1.69M | 241.99K | -1.20M | 765.99K | 506.15K |
| Change in Other Net Operating Assets | -1.47M | -1.13M | -202.18K | 255.53K | -41.85K | -200.07K |
| Operating Cash Flow | -24.67M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Long-Term Debt Repaid | -100.15K | -89.73K | -86.11K | -7.16K | ||
| Lease Payments | -104.77K | -100.15K | -89.73K | -86.11K | -7.16K | |
| Net Debt Issued (Repaid) | -104.77K | -100.15K | -89.73K | -86.11K | -7.16K | |
| Issuance of Common Stock | 293.56M | 86.03M | 900.30K | 1.47M | 6.00M | 27.84M |
| Other Financing Activities | -18.20M | -360.14K | 804.86K | -799.98K | -1.79M | |
| Financing Cash Flow | 275.26M | 85.57M | 810.57K | 2.19M | 5.20M | 26.06M |
| Foreign Exchange Rate Adjustments | 5.85M | 312.62K | 11.72K | -45.35K | 258.82K | 223.79K |
| Net Cash Flow | 256.44M | 77.19M | -1.03M | -4.88M | -8.13M | 18.96M |
| Levered Free Cash Flow | -18.77M | -4.60M | -688.05K | -4.22M | -7.58M | -3.85M |
| Unlevered Free Cash Flow | -18.74M | -4.58M | -688.05K | -4.22M | -7.58M | -3.85M |
| Change in Working Capital | 477.41K | 554.99K | 39.81K | -941.72K | 724.13K | 306.08K |
Ratios
Fiscal year October - September; amounts in CAD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 544.36M | 429.47M | 4.86M | 6.00M | 20.49M | 84.61M |
| Enterprise Value | 323.78M | 392.68M | 285.44K | 52.31K | 14.19M | 67.21M |
| Last Close Price | 54.98 | 60.66 | 1.17 | 1.60 | 6.15 | 35.71 |
| PB Ratio | 2.51 | 7.29 | 1.19 | 1.23 | 2.67 | 5.51 |
| P/TBV Ratio | 2.51 | 7.29 | 1.19 | 1.23 | 2.67 | 5.51 |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | |
| Net Debt / Equity Ratio | -1.00 | -1.01 | -1.01 | -1.01 | -1.09 | -1.02 |
| Quick Ratio | 121.44 | 35.68 | 10.91 | 24.16 | 8.00 | 31.12 |
| Current Ratio | 121.97 | 36.10 | 11.32 | 24.26 | 8.11 | 31.38 |
| Return on Equity (ROE) | -13.63% | -27.93% | -46.18% | -86.02% | -99.95% | -85.94% |
| Return on Assets (ROA) | -13.50% | -18.80% | -25.28% | -47.45% | -57.32% | -51.52% |
| Return on Capital Employed (ROCE) | -12.70% | -16.60% | -47.10% | -109.10% | -138.80% | -44.40% |
| Earnings Yield | -3.72% | -2.04% | -42.70% | -90.90% | -53.20% | -8.09% |
| Buyback Yield / Dilution | -38.94% | -59.58% | -15.87% | -50.58% | -37.64% | -148.42% |